人急性T淋巴细胞白血病细胞 Jurkat

细胞名称

人急性T淋巴细胞白血病细胞 Jurkat

货物编码

BFN60807355

产品规格

T25培养瓶x1

1.5ml冻存管x2

细胞数量

1x10^6

1x10^6

保存温度

37℃

-198℃

运输方式

常温保温运输

干冰运输

安全等级

1

用途限制

仅供科研 1类

培养体系

DMEM高糖培养基+10%FBS+1%双抗

培养温度

37℃

二氧化碳浓度

5%

简介

人急性T淋巴细胞白血病细胞Jurkat取自14岁男性供体外周血。该细胞源于DSMZ.

注释

Group: Space-flown cell line (cellonaut).

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: ENCODE project common cell types; tier 3.

Part of: International Histocompatibility Workshop cell lines.

Part of: LL-100 blood cancer cell line panel.

Doubling time: 26 hours (PubMed=17117183); ~25-35 hours (DSMZ).

Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger).

Omics: Acetylation analysis by proteomics.

Omics: Deep exome analysis.

Omics: Deep phosphoproteome analysis.

Omics: Deep proteome analysis.

Omics: Deep quantitative proteome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: N-glycan profiling.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

Omics: Ubiquitination analysis by proteomics.

Omics: Virome analysis using proteomics.

Anecdotal: Have been flown in space on Cosmos-2044 to study the inhibition of phorbol ester-induced cell activation in microgravity (PubMed=352912).

Misspelling: JURKET; In PubMed=313568.

Derived from sampling site: Peripheral blood.

基因突变

Heterozygous for BAX p.Glu41Argfs (c.121delG) and p.Glu41Glyfs (c.121dupG) (PubMed=9583678).

Heterozygous for FBXW7 p.Arg505Cys (c.1513C>T) (PubMed=22675565; Cosmic-CLP).

Heterozygous for INPP5D p.Gln345Ter (c.1033C>T) and c.1097+1065_1097+1112del47 (PubMed=19473701).

Homozygous for MSH2 p.Arg711Ter (c.2131C>T) (PubMed=9583678).

Homozygous for MSH6 p.Phe1088Serfs*2 (c.3261delC) (PubMed=9510473).

Heterozygous for NOTCH1 p.Arg1627His (c.4880G>A) (PubMed=15472075).

Heterozygous for TP53 p.Arg196Ter (c.586C>T) (PubMed=2144611; PubMed=10071127; PubMed=22675565; Cosmic-CLP).

HLA信息

/

STR信息

Amelogenin X,Y

CSF1PO 9,10,11 (RCB_RCB0537)

10,11 (Cosmic-CLP; DSMZ)

10,12 (ECACC)

11 (RCB_RCB0806)

11,12 (CCRID; COG; PubMed=28357668; TKG)

D2S1338 19,23

D3S1358 15 (CCRID)

15,16,17 (COG)

15,17 (PubMed=28357668)

D5S818 9

D7S820 8,10 (CCRID; COG; ECACC; RCB_RCB0537; TKG)

8,10,11 (Cosmic-CLP; DSMZ; RCB_RCB0806)

8,12 (PubMed=28357668)

D8S1179 13,14 (CCRID; PubMed=28357668)

12,14,15 (COG)

D13S317 8,10,11 (TKG)

8,11 (COG; Cosmic-CLP; DSMZ; ECACC; RCB_RCB0537)

8,11,12 (RCB_RCB0806)

8,12 (CCRID; PubMed=28357668)

D16S539 10,11 (ECACC; RCB_RCB0537)

11 (CCRID; COG; Cosmic-CLP; DSMZ; PubMed=28357668; RCB_RCB0806; TKG)

D18S51 13,21

D19S433 13,15.2 (COG; PubMed=28357668)

14,15.2 (CCRID)

D21S11 31.2,32.2 (COG)

31.2,33.2 (CCRID; PubMed=28357668)

FGA 20,21 (CCRID; PubMed=28357668)

20,22 (COG)

Penta D 11,13

Penta E 10,12

TH01 6,9.3

TPOX 8,9,10 (RCB_RCB0537)

8,10 (CCRID; COG; Cosmic-CLP; DSMZ; ECACC; PubMed=28357668; RCB_RCB0806; TKG)

vWA 16,17,18 (RCB_RCB0537; RCB_RCB0806)

16,17,19,20 (ECACC)

17,18,19 (COG; DSMZ)

18 (CCRID; PubMed=28357668)

18,19,20 (Cosmic-CLP)

18,20 (TKG)

参考文献

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x

Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.

The LL-100 panel: 100 cell lines for blood cancer studies.

Sci. Rep. 9:8218-8218(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023

Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K., Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.

Quantitative proteomics of the Cancer Cell Line Encyclopedia.

Cell 180:387-402(2020)